A 67-Year-Old Man With Metastatic Castrate-Sensitive Prostate Cancer - Episode 4
Charles Ryan, MD: This puts us into the situation that was highlighted by the CARD study, a major study published in the New England Journal of Medicine within the last year or so. This was 1 where they really wanted to study whether we should do cabazitaxel or another AR [androgen receptor]–targeted drug in this setting.
The CARD study enrolled patients on a 1-to-1 fashion who had previously received a therapy, who had previously received docetaxel, and who had already received either abiraterone or enzalutamide. They were randomized to receive cabazitaxel at 25 mg/m2 every 3 weeks, which is 1 of the dose regimens that we can do, or the other AR-targeted therapy.
In this case, if we were enrolling the patient on the CARD study, he would be randomized to receive either enzalutamide or cabazitaxel. It’s really testing the second AR-targeted drug versus chemotherapy.
Transcript edited for clarity.
Case: A 67-Year-Old Male with Metastatic Castrate-Sensitive Prostate Cancer
Treatment and Follow-Up